Annovis Bio Inc ANVS

Healthcare Biotechnology

Annovis Bio, Inc. is a clinical-stage drug platform company addressing neurodegeneration such as Alzheimer’s disease (AD), Parkinson’s disease (PD) and other chronic neurodegenerative diseases. The Company is developing its lead product candidate, Buntanetap, which is designed to address AD, PD, and potentially other chronic neurodegenerative diseases. Buntanetap is a synthetically produced small molecule, orally administered, brain penetrant compound. Its product candidate ANVS405 is an intravenous drug being developed for acute indications and focused on protecting the brain after traumatic brain injury (TBI) and/or stroke. ANVS405 is the same compound as Buntanetap, given in cases of acute head and brain trauma. ANVS301 is an orally administered drug being developed to increase cognitive capability in later stages of AD and dementia. ANVS301 is observed to improve memory and learning in very old rats by lowering the number of errors from six to three.

NYSE:ANVS - Post by User

Annovis Bio Inc

<< Previous

Bullboard Posts

Next >>

Post by whytestockson Nov 11, 2024 9:17pm

39 Views

Post# 36307564

InvestorNewsBreaks - Annovis Bio Inc. Advances Alzheimer's P

News; $ANVS InvestorNewsBreaks - Annovis Bio Inc. Advances Alzheimer's Phase 3 Trials with Strong FDA Support and Financial BackingAnnovis Bio (NYSE: ANVS) provided a third-quarter update, announcing significant progress in developing its lead drug candidate, buntanetap, for Alzheimer’s disease (“AD”) and Parkinson’s disease (“PD”). Following a successful Phase 2 meeting with the FD...ANVS - InvestorNewsBreaks - Annovis Bio Inc. Advances Alzheimer's Phase 3 Trials with Strong FDA Support and Financial Backing

<< Previous

Bullboard Posts

Next >>

A potential breakthrough in spinal cord and optic nerve injury treatment